- Home
- SCSC vs BCAX Comparison
SCSC vs BCAX Comparison
Compare SCSC & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCSC
- BCAX
- Stock Information
- Founded
- SCSC 1992
- BCAX 2018
- Country
- SCSC United States
- BCAX United States
- Employees
- SCSC N/A
- BCAX N/A
- Industry
- SCSC Retail: Computer Software & Peripheral Equipment
- BCAX
- Sector
- SCSC Technology
- BCAX
- Exchange
- SCSC Nasdaq
- BCAX NYSE
- Market Cap
- SCSC 732.8M
- BCAX 670.9M
- IPO Year
- SCSC 1994
- BCAX 2024
- Fundamental
- Price
- SCSC $40.38
- BCAX $9.25
- Analyst Decision
- SCSC Hold
- BCAX Strong Buy
- Analyst Count
- SCSC 1
- BCAX 7
- Target Price
- SCSC N/A
- BCAX $29.17
- AVG Volume (30 Days)
- SCSC 238.0K
- BCAX 1.1M
- Earning Date
- SCSC 05-08-2025
- BCAX 05-13-2025
- Dividend Yield
- SCSC N/A
- BCAX N/A
- EPS Growth
- SCSC N/A
- BCAX N/A
- EPS
- SCSC 2.78
- BCAX N/A
- Revenue
- SCSC $2,974,037,000.00
- BCAX N/A
- Revenue This Year
- SCSC N/A
- BCAX N/A
- Revenue Next Year
- SCSC $5.12
- BCAX N/A
- P/E Ratio
- SCSC $14.54
- BCAX N/A
- Revenue Growth
- SCSC N/A
- BCAX N/A
- 52 Week Low
- SCSC $28.75
- BCAX $7.80
- 52 Week High
- SCSC $53.90
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- SCSC 62.86
- BCAX N/A
- Support Level
- SCSC $38.03
- BCAX N/A
- Resistance Level
- SCSC $41.29
- BCAX N/A
- Average True Range (ATR)
- SCSC 1.10
- BCAX 0.00
- MACD
- SCSC -0.10
- BCAX 0.00
- Stochastic Oscillator
- SCSC 58.02
- BCAX 0.00
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.